Background: Perioperative beta-blockade is widely used, especially before vascular surgery; however, its impact on exercise performance assessed using cardiopulmonary exercise testing (CPET) in this group is unknown. We hypothesized that betablocker therapy would significantly improve CPET-derived physical fitness in this group. Methods: We recruited patients with abdominal aortic aneurysms (AAA) of <5.5 cm under surveillance. All patients underwent CPET on and off beta-blockers. Patients routinely prescribed beta-blockers underwent a first CPET on medication. Beta-blockers were stopped for one week before a second CPET. Patients not routinely taking beta-blockers underwent the first CPET off treatment, then performed a second CPET after commencement of bisoprolol for at least 48 h. Oxygen uptake ( _ V O2 ) at estimated lactate threshold (θ L ) and _ V O2 at peak were primary outcome variables. A linear mixed-effects model was fitted to investigate any difference in adjusted CPET variables on and off beta-blockers. Results: Forty-eight patients completed the study. No difference was observed in _ V O2 atθ L and _ V O2 at peak; however, a significant decrease in _ V E = _ V CO2 atθ L and peak, an increase in workload atθ L , O 2 pulse and heart rate both atθ L and peak was found with beta-blockers. Patients taking beta-blockers routinely (chronic group) had worse exercise performance (lower _ V O2 ). Conclusions: Beta blockade has a significant impact on CPET-derived exercise performance, albeit without changing _ V O2 atθ L and _ V O2 at peak. This supports performance of preoperative CPET on or off beta-blockers depending on local perioperative practice. Clinical trial registration: NCT 02106286.
Editor's key points
• This study investigated the effect of acute and chronic beta blockade on performance during CPET in vascular surgical patients.
• Oxygen uptake was lower in patients receiving beta blockers long-term.
• Initiation or withdrawal of beta blockade had no significant effect on oxygen uptake.
• There were modest but statistically significant improvements in some other CPET measurements.
• Clinicians should consider the effects of beta blockers on CPET performance in elderly vascular patients.
Beta-blockers are widely used by patients undergoing vascular surgery because of the high prevalence of cardiac disease and hypertension, and are still advocated by current guidelines to prevent perioperative cardiac complications, 1 2 despite the fact that some of the evidence in their support 3 has now been discredited. 4 5 Physical fitness, assessed by cardiopulmonary exercise testing (CPET) provides an integrated quantitative assessment of the cardiorespiratory system at rest and under the stress of maximal exercise, testing the physiological reserve required to withstand the stress of major surgery. CPET derived variables are now reliably linked to postoperative outcome after major surgery 6 7 including major vascular surgery. [8] [9] [10] The effect of perioperative beta-blockade on objectively measured physical fitness is currently unknown. This is of particular importance in vascular patients treated with chronic beta blockade, or in whom de novo perioperative beta blockade is considered. This prospective, blinded, observational study was designed to assess the effects of beta-blocker therapy on CPET derived variables in patients with abdominal aortic aneurysms (AAA). We hypothesized that beta-blocker therapy would significantly improve CPET derived physical fitness variables, which are used in the perioperative risk stratification of AAA patients. Using the results we hoped to recommend whether in this patient group preoperative CPET should be performed 'on' or 'off' beta-blockers.
Methods

Patients and study design
This study was approved by the North West -Liverpool East Research and Ethics Committee (11/NW/0810) and registered with clinicaltrials.gov (NCT02106286). Written informed consent was obtained from all patients. Between April 2012 and August 2013 we recruited consecutive, unselected patients who attended our vascular laboratory for routine AAA surveillance. We approached all patients aged >18 yrs undergoing active AAA surveillance (AAA <5.5 cms) who were able to perform a CPET, and had a WHO performance status of ≤2. We excluded patients who had a known contraindication to beta-blockers, severe ischaemic heart disease, stage IV or V chronic kidney disease, uncontrolled hypertension, those unable to consent, and absolute contraindications to CPET based on the ATS/ACCP guidelines.
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Patients were classified into 2 cohorts: (i) chronically betablocked group ( patients on long-term beta-blocker therapy at baseline) or (ii) acutely beta-blocked group ( patients not on long-term beta-blockers at baseline). All patients underwent two CPETs; one on and one off beta-blockers at least one week apart. Patients in the 'chronic' group underwent their first CPET whilst on their present medication; the beta-blocker was then stopped for at least one week before a second CPET. The 'acute' group underwent the first CPET without any alteration in medical therapy, then, at least one week later, a second CPET was performed after the commencement of bisoprolol once daily, 48 h before the test (minimum two doses, adjusted for body weight: 1.25 mg if the patient weighed 50-75 kg, 2.5 mg if 75-100 kg and 3.75 mg if >100 kg). All patients were informed of potential risks of the alteration in their medical therapy at the time of consent. The recruitment of both types of patients replicated real clinical practice where acute commencement or withdrawal of beta blockade before a perioperative CPET is routinely encountered.
Measurements
CPET (Geratherm Respiratory GmbH; Love Medical Ltd, Manchester, United Kingdom) followed a standard protocol described elsewhere. 12 CPET was reported by two experienced clinicians (MW and PW) with an experienced clinician scientist (SJ) resolving any differences. All 3 clinicians were blind to patient group allocation and beta-blocker treatment. Patient characteristics recorded included age, gender, height, weight, BMI, smoking status, haemoglobin concentration, aneurysm ultrasound details, medication details (type and dose of beta-blocker therapy) and co-morbidity, including prior patient self-reported diagnoses of diabetes, ischaemic heart disease, myocardial infarction, cerebrovascular disease, chronic obstructive pulmonary disease or heart failure. Resting flow-volume loops were used to derive Forced Expiratory Volume over 1 s (FEV1) and Forced Vital Capacity (FVC). Ventilation and gas exchange variables included oxygen uptake ( _ V O2 ) both absolute and weight adjusted, ventilatory equivalents for oxygen and carbon dioxide (
, oxygen pulse ( _ V O2 /heart rate), work rate and heart rate; all measured both at estimated lactate threshold (θ L ) and at peak exercise. Our primary objective was to assess the change in these variables caused by beta blockade after adjustment for confounders. _ V O2 atθ L and _ V O2 at peak were primary outcome variables with _ V E = _ V CO2 , workload, O 2 pulse, absolute _ V O2 and heart rate both atθ L and peak treated as exploratory outcomes.
Statistical methods
We estimated that 32 patients undergoing AAA surveillance were required in order to detect a 10% difference in _ V O2 atθ L . This estimate was based on a standard deviation of 1.5, using a two-tailed paired t-test with 90% power and allowing for a 25% drop out.
Continuous variables are summarized in terms of mean () or median (IQR) if non-normal and categorical variables are presented as frequency (%). Univariate statistical comparisons of patient characteristics between beta-blockade groups were conducted; for continuous variables, using a two-sample t-test or a Mann-Whitney U-test when non-normal and for categorical variables, using a χ 2 test or a Fisher's Exact test when cell frequencies were insufficient. For the primary analysis, a linear mixed-effects model was fitted in order to investigate any difference in CPET variables when on and off a beta-blocker. A linear regression model with robust standard errors was used where the fit was inadequate and a logtransformation of O 2 pulse was performed before analysis. Models were adjusted for beta-blockade group (chronic or acute) and a two-way interaction was investigated. Sensitivity analysis was conducted adjusting for age, gender, BMI, smoking status and Effects of beta-blockade on fitness | 879 presence of cardiac disease (myocardial infarction, heart failure or ischaemic heart disease). Model fit was assessed using residual and Q-Q plots and the adjusted estimates have been stated for each analysis. The significance level for the primary endpoint was <0.05. The P-values displayed for the exploratory endpoints were corrected for multiple comparisons using Simes's procedure and declared as significant if a P-value <0.02 was achieved.
Exploratory regression techniques were used to investigate the impact of heart rate and absolute _ V O2 on the change in O 2 pulse. Estimates produced from modelling each CPET variable separately were combined to explore how much of the change in O 2 pulse was as a result of a change in heart rate and how much was as a result of a change in _ V O2 . Results were considered significant if a P-value <0.05 was achieved. All statistical analyses were performed using Stata version 13 (StataCorp. 2013. Stata Statistical Software: release 13. College Station).
Results
We screened 252 and successfully recruited 57 patients, two of which were subsequently excluded (one patient because of a diagnosis of chronic kidney disease (stage IV) and another because of pulmonary hypertension). Fifty-five patients underwent the first CPET, 25 in the chronically beta-blocked group and 30 in the acutely beta-blocked group. Seven patients dropped out of the study between the first and the second CPET. Forty-eight patients underwent a second CPET at a median of 7 days (IQR 7-9 days) after the first CPET (20 in the 'chronic' and 28 in the 'acute' group) and completed the study (Fig. 1) . Patients in the 'chronic' group were on the after beta-blocker medications: bisoprolol (15), atenolol (7) and propranolol (3). Table 1 shows patients' characteristics in the two groups. Supplementary Table S1 shows the patients' baseline cardiovascular medications. Ischaemic heart disease and left ventricular failure were more prevalent in the chronically beta-blocked group, and lower haemoglobin values were also found. Table 2 shows a summary of the whole group CPET derived variables split according to whether the individual was prescribed ('on') or not prescribed ('off') beta-blockers before the test. Each group was subsequently divided according to whether the individual was normally prescribed a beta-blocker ('chronic') or not normally prescribed a beta-blocker ('acute'). Interobserver agreement between the two CPET reporters was very high (98%). Figure 2 illustrates changes in _ V O2 atθ L (A) and in _ V O2 at peak (B) whilst being on beta-blocker medications. An overall significantly lower resting and exercising heart rate was observed on treatment, indicating that significant beta-blockade was achieved. No adverse CPET or drug related events were recorded during the whole of the study. The results from the multivariable regression analyses and the effect of beta-blockade on the whole groups' CPET variables are shown in Table 3 . After adjustment for confounding variables, we found that taking beta-blockers resulted in no difference in _ V O2 atθ L and _ V O2 at peak. However, there was a significant decrease in _ V E = _ V CO2 atθ L and peak in patients taking beta-blockers in comparison to those not taking beta-blockers and a significant increase in workload atθ L , but not at peak. Finally, a significantly higher O 2 pulse atθ L and peak was found during CPET in those taking beta-blockers along with a significant decrease in heart rate atθ L and peak. The increase seen in O 2 pulse was primarily related to a change in heart rate rather than a change in absolute _ V O2 : atθ L , the decrease in heart rate was associated with a 12.4% increase in O 2 pulse compared with a 2.4% increase associated with a change in absolute _ V O2 (similarly at peak: 8.1 vs 0.3% increase). Table 3 also shows the effect of beta-blockade on CPET variables in patients usually prescribed ('chronic') vs those not usually prescribed ('acute') beta-blockers. After adjustment for confounding variables, a significantly lower _ V O2 atθ L and _ V O2 at peak was found in patients in the 'chronic' beta-blockade group compared with those in the 'acute' beta-blockade group. We found no difference between the groups in the remaining CPET variables.
Discussion
We found that, in patients with AAA, beta blockade led to no significant improvement in our primary outcome measures _ V O2 atθ L or peak (albeit the increase in _ V O2 atθ L fell just short of statistical significance) but did have a significant impact on the other exploratory CPET variables. Beta-blockade improved exercise performance evidenced by a significantly increased workload at θ L , decreased heart rate and _ V E = _ V CO2 at bothθ L and peak exercise, and increased O 2 pulse atθ L and at peak. The primary determinant of the increase in O 2 pulse both atθ L and peak exercise was the decrease in heart rate. Additionally, we found that patients who were chronically beta-blocked had generally worse performance on CPET, regardless of whether the CPET is performed on or off medications. This finding was independent of the presence of any cardiac disease.
The findings of our study mirror the complex effects that betablockers are known to have on cardio-respiratory physiology, albeit predominantly in patients with cardiac failure. Beyond the in keeping with our findings. Beta-blockers, as we found in our patients, improve _ V E = _ V CO2 , 15 an effect mediated by β 1 and, in particular, β 2 adrenergic receptors, whose blockade improves diffusion capacity. 16 In contrast the effect of beta-blockers on healthy individuals is opposite, with reduced _ V O2 , exercise tolerance and ventilatory equivalents. 17 Hence, the behaviour of our patients resembled the expected response pattern of a population with cardiac failure rather than healthy volunteers. To our knowledge this is the first study to investigate the impact of beta-blockade on CPET performance in a preoperative setting, studying elderly patients with a significant prevalence of cardiovascular risk factors, but a low prevalence of overt cardiac failure. As CPET is commonly and increasingly used in the preoperative assessment of these patients, clinicians must decide whether to perform the test on or off beta-blockers. Beta-blockade during CPET reduces the test's ability to detect significant myocardial ischaemia, an important prognostic indicator. However, it is logical to assess the patient under conditions experienced during and after surgery, when beta-blockade is recommended to be continued to avoid cardiac complications.
2 Acute beta-blockade before vascular surgery has been widely used to prevent perioperative myocardial ischaemia, although its benefit is often offset by an increased incidence of non-cardiac complications. 5 Our study shows that a CPET test performed whilst on beta-blockers will lead to a somewhat 'better' exercise performance than if the test is done off the medications. Hence, if perioperative acute beta-blockade is usual practice the preoperative test should probably be performed on beta-blockers. Data in Figure 2 shows a variation in individual patient parameters; especially _ V O2 Peak (Panel B); however, we were unable to identify specific characteristics which would explain these individual variations. A larger study would be needed to investigate these potentially important variations. Table 2 Spirometry and CPET, measured at rest,θ L and peak, in the whole group and divided according to whether the test was performed when taking ('on') or not taking ('off') beta-blockers. These groups are then sub-divided according to whether the subject was normally prescribed ('chronic') or not normally prescribed ('acute') a beta-blocker. Values presented as mean () Beta-blockers are often used chronically by patients undergoing aortic surgery, as these individuals have a high prevalence of ischaemic heart disease, hypertension, cardiac failure and arrhythmias (as evidenced by our cohort). In general, this cohort display worse exercise performance than those not on longterm beta-blocker therapy irrespective of the presence of cardiac disease. However, the effect of beta-blockade is similar and there appears no reason to withdraw the beta-blocker before preoperative CPET testing. The decision to initiate perioperative betablockade and its relationship to surgical outcomes and survival remains, in many cases, highly controversial and beyond the scope of this study.
Strengths of this study include the robust methodology by which the CPET was performed. CPET interpretation was carried out in a blinded fashion by 2 experienced clinicians (with a high degree of interobserver agreement), with resolution of any discrepancies by a third experienced clinician scientist. All resting CPET data were taken between minute 2 and 3 to negate the effects of any acute hyperventilation. The patient cohort was an unselected group of AAA patients under surveillance which readily mimic a typical perioperative vascular patient cohort. Finally, the significantly lower heart rate in subjects taking beta-blockers, regardless of whether prescribed normally shows that the protocol produced an appropriate physiological response.
Potential limitations include the use of different medications at different dosages by chronically beta-blocked patients, with differing degrees of cardioselectivity and intrinsic sympathomimetic activity. This group was formed by patients in whom Results presented according to whether subjects were taking a beta-blocker at the time of testing ('Whole group beta-blocked vs not'). Results also presented according to whether the subjects were routinely prescribed a beta-blocker or not ('Acute vs chronic betablockade'). _ V O2 , Oxygen uptake;θ L , estimated lactate threshold; _ V E = _ V CO2 , Ventilatory equivalent for carbon dioxide. _ V O2 atθ L and _ V O2 at peak were primary outcome variables and are declared as significant with a P-value of <0.05*. All other exploratory variables are declared as significant with a corrected critical P-value value of ≤0.02.
1'
Beta-blocked vs not' denotes the effect of beta-blockade vs no beta-blockade in the whole group. 2 'Acute vs chronic' denotes the effect of beta-blockade comparing those normally prescribed beta-blockers (chronic) with those not normally prescribed (actue) beta-blockers Effects of beta-blockade on fitness | 883 medical therapy was deemed adequate by their treating physicians, and represents a typical population encountered in a preoperative assessment setting. In clinical practice it would be unusual to switch the specific beta-blocker before surgery so our 'pragmatic' protocol closely reflects real practice. For acute beta-blockade, we chose bisoprolol because it is a highly selective β 1 blocker, 18 off patent and most commonly used in local clinical practice (as seen in the 'chronic' group). We do not believe that a different medication would have produced a markedly different effect but we cannot rule this out. Although the subjects showed a reduction in heart rate with beta-blockade the degree of betablockade will have been variable in between patients. Furthermore, there was scope to further increase the beta-blocker dose in some patients and this could have potentiated any effect on exercise performance. However, our study mirrors real life practice where this titration would not be routine.
Although we saw a trend towards higher _ V O2 values with betablockers, we could not demonstrate a statistically significant difference, possibly because of too small a sample size (albeit adequately powered, according to our assumptions and previously published data). Larger numbers would also be necessary to study the interactions of beta-blockers with other cardiorespiratory medications, which we did not evaluate, and may help to explain the different responses of individual patients. A much larger study would also be necessary to identify patients' characteristics associated with a 'positive' response to beta-blockade.
We have shown that only a small number of subjects were diagnosed with or treated for COPD although the presence of airflow obstruction (mostly mild) was common, suggesting significant under-diagnosis. However, in both the acute and chronic groups commencement of beta-blockers had little effect on spirometric measures of airflow obstruction (FEV1 and FEV1/FVC).
Our study shows that, in patients with AAA, beta-blockade improved exercise performance evidenced by a significantly increased workload atθ L , decreased heart rate and _ V E = _ V CO2 at bothθ L and peak exercise. Although a significant difference was seen in the O 2 pulse atθ L and peak exercise, this was as a result of a change in heart rate and not a change in _ V O2 . Furthermore, we did not demonstrate a significant difference in _ V O2 atθ L or peak. Patients already taking long term beta-blocker therapy were generally less physically fit both whilst taking long term beta-blockers and when these were stopped. In light of this we suggest that beta-blockade before/during preoperative CPET testing should mirror the perioperative practice of the centre. This study may also guide clinicians in charge of the perioperative management of such patients as to likely CPET response on and off beta-blocker treatment.
